KPV

Last Updated: May 2026

KPV (Lys-Pro-Val) is the anti-inflammatory C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH), researched for gut inflammation, skin barrier repair, and broad NF-κB-mediated inflammatory pathway inhibition. It is one of the better-studied small anti-inflammatory peptides with preclinical and early clinical evidence in inflammatory bowel disease contexts. Important regulatory update: KPV was removed from the FDA's Category 2 bulk substances list on April 22, 2026 and is scheduled for PCAC review in July 2026.

What is KPV and how does the α-MSH-derived anti-inflammatory mechanism work?

KPV is the C-terminal tripeptide of α-MSH (alpha-melanocyte-stimulating hormone), retaining the anti-inflammatory activity of the parent hormone while losing the melanocortin receptor binding responsible for pigmentation effects. KPV inhibits NF-κB signaling, reduces pro-inflammatory cytokine production, and modulates immune cell function — particularly in epithelial tissues. The compound's small size (3 amino acids) supports oral bioavailability for gut-targeted indications. Evidence level: Preclinical extensive (inflammatory bowel disease, skin inflammation, oral biology); limited human clinical.

What does the research show for KPV?

Preclinical studies have demonstrated reduced colonic inflammation in IBD models, accelerated skin barrier repair in wound healing models, and reduced periodontal inflammation in dental research contexts. Human clinical trials specifically for KPV remain limited but the compound has been incorporated into some clinical and complementary care protocols for gut and skin inflammation. Evidence level: Preclinical extensive across inflammation models; human clinical limited.

How does KPV compare to other anti-inflammatory peptides?

KPV operates through NF-κB inhibition at very small molecular size, distinguishing it from longer anti-inflammatory peptides like BPC-157 (which acts through different mechanisms — angiogenesis, growth factor signaling) and from broader immune modulators like Thymosin Alpha-1.

What are the documented side effects of KPV?

KPV's safety profile in preclinical studies and available human research use has been favorable — the most common report is mild injection-site reactions (for injectable use) or no notable effects (for oral/topical use). The small size and α-MSH-derived origin support a low side-effect burden. Long-term safety at sustained research-use dosing is not characterized at Western RCT standards. Evidence level: Preclinical safety; human long-term unestablished.

What is the regulatory status of KPV?

KPV is not approved for any medical indication anywhere in the world as of May 2026. On April 22, 2026, KPV was removed from the FDA's Category 2 bulk substances list and is scheduled for Pharmacy Compounding Advisory Committee (PCAC) review in July 2026. Removal from Category 2 does not authorize compounding — formal Category 1 inclusion or 503A bulks list addition remains pending PCAC determination. Current status in FDA peptide regulation 2025–2026 timeline.

Why does KPV vendor verification matter?

KPV's short tripeptide structure (Lys-Pro-Val) makes synthesis straightforward and broadly available, but identity verification still matters — and the small molecular weight (~342 Da) requires mass spectrometry confirmation. Independent HPLC purity testing is the standard quality signal. Guidance in how-to-test-peptides hub.

How does Peptigrity verify KPV vendors?

Peptigrity purchases KPV vials anonymously at standard customer pricing, sends them to ISO-accredited third-party labs for HPLC and mass spectrometry analysis, and publishes the unedited certificate of analysis. Methodology in how we calculate trust scores.

Frequently Asked Questions

What does KPV do?

KPV is researched for anti-inflammatory effects through NF-κB pathway inhibition, with preclinical evidence in inflammatory bowel disease, skin barrier repair, and oral inflammation. Human clinical evidence is more limited than the preclinical base.

Is KPV legal to purchase?

KPV is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption. The April 22, 2026 Category 2 removal opens a potential future compounding pathway pending PCAC review in July 2026. Country breakdown in peptide legal status guide.

When will the FDA decide on KPV?

KPV is scheduled for Pharmacy Compounding Advisory Committee (PCAC) review in July 2026. Removal from Category 2 in April 2026 was a procedural step; formal authorization for compounding pharmacy production remains pending PCAC determination. Track developments in FDA peptide regulation 2025–2026 timeline.

Can KPV be taken orally?

KPV's small size (3 amino acids) supports better oral bioavailability than longer peptides, and oral KPV has been used in research and clinical contexts for gut-targeted indications. Injectable, oral, and topical formulations are all represented in research-grade vendor markets.

How can I verify a KPV vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation (expected MW ~342 Da). COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend a KPV dose?

No. KPV is not approved for human consumption and Peptigrity is an independent review platform, not a medical authority. Research-use dosing in community protocols varies by route. Anyone considering use should consult a licensed physician.

This section is for educational and informational purposes only and does not constitute medical advice. KPV is not approved by the FDA or any major Western regulator for human use, though it was removed from Category 2 of the FDA 503A bulk substances list in April 2026 and is scheduled for PCAC review in July 2026. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.